Tyra Biosciences Quarterly Cash Flow Statement
NASDAQ: TYRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.94-0.03 (-0.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tyra Biosciences free cash flow
In the quarter ended Jun 30, 2026, Tyra Biosciences generated -$31.1 million of operating cash flow and spent $66,000 on capital expenditures. That left free cash flow of -$31.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Tyra Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -45.56M | -39.30M | -33.83M | -29.87M | -28.10M | -28.15M | -25.57M | -24.02M | -18.70M | -18.19M | -22.83M | -21.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 138.00K | 138.00K | 132.00K | 131.00K | 140.00K | 143.00K | 144.00K | 127.00K | 126.00K | 122.00K | 102.00K | 83.00K |
| Stock-Based Compensation | 10.23M | 7.85M | 7.63M | 7.58M | 6.38M | 6.42M | 6.70M | 7.57M | 4.41M | 4.12M | 4.19M | 4.38M |
| Change in Working Capital | 5.32M | 1.20M | 2.16M | 2.07M | -491.00K | -365.00K | 2.21M | 2.01M | 1.94M | -6.91M | 5.08M | 4.64M |
| Operating Cash Flow | -31.08M | -32.57M | -23.62M | -22.38M | -23.68M | -25.46M | -19.59M | -17.90M | -10.26M | -22.03M | -13.53M | -17.14M |
| Capital Expenditures | -66.00K | -88.00K | -57.00K | -39.00K | -31.00K | -14.00K | -6.00K | -52.00K | -470.00K | -136.00K | -603.00K | -83.00K |
| Investing Cash Flow | 17.85M | -120.24M | 34.38M | -14.81M | 20.87M | 32.03M | 6.96M | 21.56M | -144.99M | 18.07M | -144.44M | -83.00K |
| Financing Cash Flow | 2.10M | 160.38M | 4.68M | 647.00K | 583.00K | 2.19M | 706.00K | 743.00K | 373.00K | 200.31M | 324.00K | 467.00K |
| Net Change in Cash | -11.12M | 7.57M | 15.44M | -36.54M | -2.23M | 8.76M | -11.93M | 4.40M | -154.88M | 196.36M | -157.65M | -16.76M |
| Free Cash Flow | -31.14M | -32.66M | -23.68M | -22.42M | -23.71M | -25.47M | -19.60M | -17.95M | -10.73M | -22.16M | -14.13M | -17.23M |
This table shows 12 quarterly periods of Tyra Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TYRA's reporting calendar. What is a cash flow statement?